Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
FEBS J ; 291(10): 2221-2241, 2024 May.
Article in English | MEDLINE | ID: mdl-38400523

ABSTRACT

It was reported that the Wnt/ß-catenin pathway is involved in the regulation of aerobic glycolysis and that brain glycolytic dysfunction results in the development of Alzheimer's disease (AD). Icariin (ICA), an active component extracted from Epimedii Folium, has been reported to produce neuroprotective effects in multiple models of AD, but its underlying mechanism remains to be fully described. We aimed to investigate the protective effects of ICA on animal and cell models of AD and confirm whether the Wnt/ß-catenin pathway has functions in the neuroprotective function of ICA. The 3 × Tg-AD mice were treated with ICA. HT22 cells, the Aß25-35 peptide and Dickkopf-1 (DKK1) agent (a specific inhibitor of the Wnt/ß-catenin pathway) were used to further explore the underlying mechanism of ICA that produces anti-AD effects. Behavioral examination, western blotting assay, staining analysis, biochemical test, and lactate dehydrogenase (LDH) assays were applied. We first demonstrated that ICA significantly improved cognitive function and autonomous behavior, reduced neuronal damage, and reversed the protein levels and activities of glycolytic key enzymes, and expression of protein molecules of the canonical Wnt signaling pathway, in 3 × Tg-AD mice back to wild-type levels. Next, we further found that ICA increased cell viability and effectively improved the dysfunctional glycolysis in HT22 cells injured by Aß25-35. However, when canonical Wnt signaling was inhibited by DKK1, the above effects of ICA on glycolysis were abolished. In summary, ICA exerts neuroprotective effects in 3 × Tg-AD animals and AD cellular models by enhancing the function of glycolysis through activation of the Wnt/ß-catenin pathway.


Subject(s)
Alzheimer Disease , Disease Models, Animal , Flavonoids , Glycolysis , Mice, Transgenic , Wnt Signaling Pathway , Animals , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Wnt Signaling Pathway/drug effects , Glycolysis/drug effects , Flavonoids/pharmacology , Mice , Amyloid beta-Peptides/metabolism , beta Catenin/metabolism , beta Catenin/genetics , Neuroprotective Agents/pharmacology , Intercellular Signaling Peptides and Proteins/metabolism , Intercellular Signaling Peptides and Proteins/genetics , Peptide Fragments/metabolism , Male
2.
Front Aging Neurosci ; 15: 1218267, 2023.
Article in English | MEDLINE | ID: mdl-37744386

ABSTRACT

Objective: To investigate the mechanism of RNA-binding protein hnRNP A1 in mouse hippocampal neurons (HT22) on glycolysis. Methods: RIP and CLIP-qPCR were performed by HT22 in vitro to observe the mechanism of hnRNP A1 regulating the expression of key proteins in glycolysis. The RNA binding domain of hnRNP A1 protein in HT22 was inhibited by VPC-80051, and the effect of hnRNP A1 on glycolysis of HT22 was observed. Lentivirus overexpression of hnRNP A1 was used to observe the effect of overexpression of hnRNP A1 on glycolysis of Aß25-35-injured HT22. The expression of hnRNP A1 in brain tissues of wild-type mice and triple-transgenic (APP/PS1/Tau) AD mice at different ages was studied by Western blot assay. Results: The results of RIP experiment showed that hnRNP A1 and HK1 mRNA were significantly bound. The results of CLIP-qPCR showed that hnRNP A1 directly bound to the 2605-2821 region of HK1 mRNA. hnRNP A1 inhibitor can down-regulate the expression of HK1 mRNA and HK1 protein in HT22 cells. Overexpression of hnRNP A1 can significantly reduce the toxic effect of Aß25-35 on neurons via the hnRNP A1/HK1/ pyruvate pathway. In addition, inhibition of hnRNP A1 binding to amyloid precursor protein (APP) RNA was found to increase Aß expression, while Aß25-35 also down-regulated hnRNP A1 expression by enhancing phosphorylation of p38 MAPK in HT22. They interact to form bidirectional regulation, further down-regulating the expression of hnRNP A1, and ultimately aggravating glycolytic dysfunction. Protein immunoblotting showed that hnRNP A1 decreased with age in mouse brain tissue, and the decrease was greater in AD mice, suggesting that the decrease of hnRNP A1 may be a predisposed factor in the pathogenesis of AD.

3.
ISA Trans ; 119: 208-220, 2022 Jan.
Article in English | MEDLINE | ID: mdl-33648733

ABSTRACT

Back-stepping design method is widely used in high-performance tracking control tasks As is known to all, the controller based on back-stepping design will become complex as the model order increases, which is the so called "explosion of terms" problem. In this paper, a tracking differentiator (TD) based back-stepping controller is proposed to handle the "explosion of terms" problem. Instead of calculating the derivatives of intermediate control variables through tedious analytical expressions, for the proposed method, the tracking differentiator is embedded into each recursive procedure to generate the substitute derivative signal for every intermediate control variable. As a result, the complexity of implementation procedure of back-stepping controller is significantly reduced. The discrepancies between the derivative substitutes and the real derivatives are considered. And the effects on control performances caused by the discrepancies are analyzed. In addition to giving the theoretical results and the stability proofs with Lyapunov methods, the developed controller design method is evaluated through a series of experiments with a hydraulic robot arm position serve system. The control performance of the proposed controller is verified by the experiments results.

SELECTION OF CITATIONS
SEARCH DETAIL
...